Search

Your search keyword '"Meites, Elissa"' showing total 241 results
Start Over Author "Meites, Elissa" Language english
241 results on '"Meites, Elissa"'

2. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021

Author

SUPERNOVA COVID-19 Surveillance Group, Bajema, Kristina L., Dahl, Rebecca M., Evener, Steve L., Prill, Mila M., Rodriguez-Barradas, Maria C., Marconi, Vincent C., Beenhouwer, David O., Holodniy, Mark, Lucero-Obusan, Cynthia, Brown, Sheldon T., Tremarelli, Maraia, Epperson, Monica, Mills, Lisa, Park, So Hee, Rivera-Dominguez, Gilberto, Morones, Rosalba Gomez, Ahmadi-Izadi, Ghazal, Deovic, Rijalda, Mendoza, Chad, Jeong, Chan, Schrag, Stephanie J., Meites, Elissa, Hall, Aron J., Kobayashi, Miwako, McMorrow, Meredith, Verani, Jennifer R., Thornburg, Natalie J., and Surie, Diya

Published
2021

3. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021

Author

SUPERNOVA COVID-19 Surveillance Group, Bajema, Kristina L., Dahl, Rebecca M., Prill, Mila M., Meites, Elissa, Rodriguez-Barradas, Maria C., Marconi, Vincent C., Beenhouwer, David O., Brown, Sheldon T., Holodniy, Mark, Lucero-Obusan, Cynthia, Rivera-Dominguez, Gilberto, Morones, Rosalba Gomez, Whitmire, Alexis, Goldin, Evan B., Evener, Steve L., Tremarelli, Maraia, Tong, Suxiang, Hall, Aron J., Schrag, Stephanie J., McMorrow, Meredith, Kobayashi, Miwako, Verani, Jennifer R., and Surie, Diya

Published
2021

4. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Author

Wei, Feixue, Gaisa, Michael M, D'Souza, Gypsyamber, Xia, Ningshao, Giuliano, Anna R, Hawes, Stephen E, Gao, Lei, Cheng, Shu-Hsing, Donà, Maria Gabriella, Goldstone, Stephen E, Schim van der Loeff, Maarten F, Neukam, Karin, Meites, Elissa, Poynten, I Mary, Dai, Jianghong, Combes, Jean-Damien, Wieland, Ulrike, Burgos, Joaquin, Wilkin, Timothy J, Hernandez, Alexandra L, Iribarren Díaz, Mauricio, Hidalgo-Tenorio, Carmen, Valencia Arredondo, Marleny, Nyitray, Alan G, Wentzensen, Nicolas, Chow, Eric PF, Smelov, Vitaly, Nowak, Rebecca G, Phanuphak, Nittaya, Woo, Yin Ling, Choi, Yoojin, Hu, Yifei, Schofield, Alice M, Woestenberg, Petra J, Chikandiwa, Admire T, Hickey, Andrew C, de Pokomandy, Alexandra, Murenzi, Gad, Péré, Hélène, del Pino, Marta, Ortiz, Ana P, Charnot-Katsikas, Angella, Liu, Xing, Chariyalertsak, Suwat, Strong, Carol, Ong, Jason J, Yunihastuti, Evy, Etienney, Isabelle, Ferré, Valentine M, Zou, Huachun, Segondy, Michel, Chinyowa, Simbarashe, Alberts, Catharina J, and Clifford, Gary M

Published
2021
Full Text
View/download PDF

17. Sexually Transmitted Diseases Among Pregnant Women: 5 States, United States, 2009-2011

Author

Williams, Charnetta L., Harrison, Leslie L., Llata, Eloisa, Smith, Ruben A., and Meites, Elissa

Subjects
Sexually transmitted diseases -- Control -- Care and treatment, Pregnancy complications, Health care industry
Abstract

Introduction Screening for specific sexually transmitted diseases (STDs) during pregnancy has been a longstanding public health recommendation. Prior studies have described associations between these infections and socioeconomic factors such as race/ethnicity and education. Objectives We evaluated the prevalence of STDs and the correlation socioeconomic factors have with the presence of these infections among pregnant women in the United States. Methods We conducted an analysis using self-reported data from 12,948 recently pregnant women from the Pregnancy Risk Assessment Monitoring System (PRAMS) in 5 states during 2009-2011. Responses to questions about curable STDs (chlamydia, gonorrhea, syphilis, trichomoniasis) diagnosed during pregnancy were utilized to calculate weighted STD prevalence estimates and 95% confidence intervals (CI). A logistic regression was also conducted to identify maternal socioeconomic characteristics significantly associated with STDs; results are displayed as adjusted prevalence ratios (aPR). The PRAMS protocol was approved at PRAMS participating sites and by CDC's Institutional Review Board. Results Overall, 3.3% (CI 2.9-3.7) reported [greater than or equal to] 1 curable STD during her most recent pregnancy. The adjusted STD prevalence was higher among women with younger age (aPR, 2.4; CI 1.8-3.4), non-Hispanic black race/ethnicity (aPR, 3.3; CI 2.4-4.1), unmarried status (aPR, 2.1; CI 1.4-3.0), no college education (aPR, 1.4; CI 1.0-1.9), annual income < $25,000 (aPR, 2.0; CI 1.3-3.2), and no pre-pregnancy health insurance (aPR, 1.4; CI 1.1-1.8). Conclusions for Practice This is the largest study of prevalence of self-reported curable STDs among U.S. pregnant women. Differences in STD prevalence highlight the association between certain socioeconomic factors and the presence of STDs., Author(s): Charnetta L. Williams [sup.1] [sup.2] , Leslie L. Harrison [sup.3] , Eloisa Llata [sup.2] , Ruben A. Smith [sup.3] , Elissa Meites [sup.2] Author Affiliations: (Aff1) 0000 0001 2163 [...]

Published
2018
Full Text
View/download PDF

23. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans---Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021

Author

Bajema, Kristina L., Dahl, Rebecca M., Evener, Steve L., Prill, Mila M., Rodriguez-Barradas, Maria C., Marconi, Vincent C., Beenhouwer, David O., Holodniy, Mark, Lucero-Obusan, Cynthia, Brown, Sheldon T., Tremarelli, Maraia, Epperson, Monica, Mills, Lisa, Park, So Hee, Rivera-Dominguez, Gilberto, Morones, Rosalba Gomez, Ahmadi-Izadi, Ghazal, Deovic, Rijalda, Mendoza, Chad, Jeong, Chan, Schrag, Stephanie J., Meites, Elissa, Hall, Aron J., Kobayashi, Miwako, McMorrow, Meredith, Verani, Jennifer R., Thornburg, Natalie J., and Surie, Diya

Subjects
Johnson & Johnson, Pfizer Inc., Medical centers, Hospitals, Veterans', RNA, Vaccines, Pharmaceutical industry, Health
Abstract

The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining [...]

Published
2021

26. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization--Five Veterans Affairs Medical Centers, United States, February 1-August 6, 2021

Author

Bajema, Kristina L., Dahl, Rebecca M., Prill, Mila M., Meites, Elissa, Rodriguez-Barradas, Maria C., Marconi, Vincent C., Beenhouwer, David O., Brown, Sheldon T., Holodniy, Mark, Lucero-Obusan, Cynthia, Rivera-Dominguez, Gilberto, Morones, Rosalba Gomez, Whitmire, Alexis, Goldin, Evan B., Evener, Steve L., Tremarelli, Maraia, Tong, Suxiang, Hall, Aron J., Schrag, Stephanie J., McMorrow, Meredith, Kobayashi, Miwako, Verani, Jennifer R., and Surie, Diya

Subjects
Johnson & Johnson, Pfizer Inc., Medical research, Medicine, Experimental, Medical centers, Hospitals, Veterans', Messenger RNA, Vaccines, Health
Abstract

On September 10, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.govlmmwr). COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) have been shown to be highly [...]

Published
2021

32. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors — Final Report

Author

Deen, Gibrilla F., Broutet, Nathalie, Xu, Wenbo, Knust, Barbara, Sesay, Foday R., McDonald, Suzanna L.R., Ervin, Elizabeth, Marrinan, Jaclyn E., Gaillard, Philippe, Habib, Ndema, Liu, Hongtu, Liu, William, Thorson, Anna E., Yamba, Francis, Massaquoi, Thomas A., James, Faustin, Ariyarajah, Archchun, Ross, Christine, Bernstein, Kyle, Coursier, Antoine, Klena, John, Carino, Marylin, Wurie, Alie H., Zhang, Yong, Dumbuya, Marion S., Abad, Neetu, Idriss, Baimba, Wi, Teodora, Bennett, Sarah D., Davies, Tina, Ebrahim, Faiqa K., Meites, Elissa, Naidoo, Dhamari, Smith, Samuel J., Ongpin, Patricia, Malik, Tasneem, Banerjee, Anshu, Erickson, Bobbie R., Liu, Yongjian, Liu, Yang, Xu, Ke, Brault, Aaron, Durski, Kara N., Winter, Jörn, Sealy, Tara, Nichol, Stuart T., Lamunu, Margaret, Bangura, James, Landoulsi, Sihem, Jambai, Amara, Morgan, Oliver, Wu, Guizhen, Liang, Mifang, Su, Qiudong, Lan, Yu, Hao, Yanzhe, Formenty, Pierre, Ströher, Ute, and Sahr, Foday

Published
2017
Full Text
View/download PDF

33. HPV Vaccine Implementation in STD Clinics—STD Surveillance Network

Author

Meites, Elissa, Llata, Eloisa, Hariri, Susan, Zenilman, Jonathan, Longfellow, Lisa, Schwebke, Jane, Tabidze, Irina, Mettenbrink, Christie, Jenkins, Heidi, Guerry, Sarah, Pathela, Preeti, Asbel, Lenore, Stover, Jeffrey A., Bernstein, Kyle, Kerani, Roxanne P., Dunne, Eileen F., and Markowitz, Lauri E.

Published
2012

35. Transmission of 2009 Pandemic Influenza A (H1N1) Virus among Healthcare Personnel—Southern California, 2009

Author

Jaeger, Jenifer L., Patel, Minal, Dharan, Nila, Hancock, Kathy, Meites, Elissa, Mattson, Christine, Gladden, Matt, Sugerman, David, Doshi, Saumil, Blau, Dianna, Harriman, Kathleen, Whaley, Melissa, Sun, Hong, Ginsberg, Michele, Kao, Annie S., Kriner, Paula, Lindstrom, Stephen, Jain, Seema, Katz, Jacqueline, Finelli, Lyn, Olsen, Sonja J., and Kallen, Alexander J.

Published
2011
Full Text
View/download PDF

38. COVID-19 Scientific Publications From the Centers for Disease Control and Prevention, January 2020–January 2022.

Author

Meites, Elissa, Knuth, Martha, Hall, Kaely, Dawson, Patrick, Wang, Teresa W., Wright, Marcienne, Yu, Wei, Senesie, Schabbethai, Stephenson, Elizabeth, Imachukwu, Chukwuebuka, Sayi, Takudzwa, Gurbaxani, Brian, Svendsen, Erik R., Khoury, Muin J., Ellis, Barbara, and King, Brian A.

Subjects
*COVID-19, *SERIAL publications, *BIBLIOMETRICS, *SOCIAL media, *COVID-19 vaccines, *TREATMENT effectiveness, *QUALITY assurance, *DESCRIPTIVE statistics, *HEALTH equity, *COVID-19 pandemic, *PATIENT safety
Abstract

Objective: High-quality scientific evidence underpins public health decision making. The Centers for Disease Control and Prevention (CDC) agency provides scientific data, including during public health emergencies. To understand CDC's contributions to COVID-19 science, we conducted a bibliometric evaluation of publications authored by CDC scientists from January 20, 2020, through January 20, 2022, by using a quality improvement approach (SQUIRE 2.0). Methods: We catalogued COVID-19 articles with ≥1 CDC-affiliated author published in a scientific journal and indexed in the World Health Organization's COVID-19 database. We identified priority topic areas from the agency's COVID-19 Public Health Science Agenda by using keyword scripts in EndNote and then assessed the impact of the published articles by using Scopus and Altmetric. Results: During the first 2 years of the agency's pandemic response, CDC authors contributed to 1044 unique COVID-19 scientific publications in 208 journals. Publication topics included testing (n = 853, 82%); prevention strategies (n = 658, 63%); natural history, transmission, breakthrough infections, and reinfections (n = 587, 56%); vaccines (n = 567, 54%); health equity (n = 308, 30%); variants (n = 232, 22%); and post–COVID-19 conditions (n = 44, 4%). Publications were cited 40 427 times and received 81 921 news reports and 1 058 893 social media impressions. As the pandemic evolved, CDC adapted to address new scientific questions, including vaccine effectiveness, safety, and access; viral variants, including Delta and Omicron; and health equity. Conclusion: The agency's COVID-19 Public Health Science Agenda helped guide impactful scientific activities. CDC continues to evaluate COVID-19 priority topic areas and contribute to development of new scientific work. CDC is committed to monitoring emerging issues and addressing gaps in evidence needed to improve health. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Changes in Strength of Recommendation and Perceived Barriers to HPV Vaccination: Longitudinal Analysis of Primary Care Physicians, 2008–2018

Author

Cataldi, Jessica R., O’Leary, Sean T., Markowitz, Lauri E., Allison, Mandy A., Crane, Lori A., Hurley, Laura P., Brtnikova, Michaela, Beaty, Brenda L., Gorman, Carol, Meites, Elissa, Lindley, Megan C., and Kempe, Allison

Subjects
Male, Parents, Health Knowledge, Attitudes, Practice, Adolescent, Primary Health Care, Attitude of Health Personnel, Papillomavirus Infections, Vaccination, Pediatrics, Article, Vaccination Refusal, Surveys and Questionnaires, Humans, Female, Longitudinal Studies, Papillomavirus Vaccines, Child
Abstract

OBJECTIVES: To evaluate among pediatricians) and family physicians (how HPV vaccination recommendation practices for 11–12 year-old youth; reported parental refusal/ deferral of HPV vaccination; and reported barriers to HPV vaccination changed over time:. STUDY DESIGN: We surveyed nationally representative networks of pediatricians and family physicians in 2008, 2010, 2013–2014 and 2018. Male vaccination questions were not asked in 2008; barriers and parental vaccine refusal questions were not asked in 2010. RESULTS: Response rates were 80% in 2008 (680/848), 72% in 2010 (609/842), 70% in 2013–2014 (582/829), and 65% in 2018 (588/908). The proportion of physicians strongly recommending HPV vaccination for 11–12 year-old patients increased from 53% in 2008 to 79% in 2018 for female patients, and from 48% in 2014 to 76% in 2018 for male patients (both p

Published
2021

40. Reemerging leptospirosis, California

Author

Meites, Elissa, Jay, Michele T., Deresinski, Stanley, Shieh, Wun-Ju, Zaki, Sherif R., Tompkins, Lucy, and Smith, D. Scott

Subjects
Leptospirosis -- Research
Abstract

Leptospirosis is a reemerging infectious disease in California. Leptospirosis is the most widespread zoonosis throughout the world, though it is infrequently diagnosed in the continental United States. From 1982 to [...]

Published
2004

45. Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women.

Author

Winer, Rachel L, Lin, John, Querec, Troy D, Unger, Elizabeth R, Stern, Joshua E, Rudd, Jessica M, Golden, Matthew R, Swanson, Fred, Markowitz, Lauri E, and Meites, Elissa

Subjects
TRANSGENDER people, VACCINATION status, VACCINE effectiveness, VACCINATION, PAPILLOMAVIRUSES
Abstract

Background: In the United States, human papillomavirus (HPV) vaccination has been recommended since 2011 for boys aged 11-12 years, with catch-up vaccination recommended through age 26 years for previously unvaccinated men who have sex with men (MSM).Methods: During 2016-2018, a cross-sectional study enrolled MSM and transgender women aged 18-26 years in Seattle, Washington. Participants submitted self-collected penile swab specimens for HPV genotyping. HPV vaccination history was self-reported. We compared HPV prevalence among vaccinated participants with that in participants with no or unknown vaccination history, using log-binomial regression to estimate adjusted prevalence ratios and confidence intervals.Results: Among 687 participants, 348 (50.7%) self-reported ever receiving ≥1 HPV vaccine dose; the median age at first HPV vaccination was 21 years, and the median age at first sex, 17 years. Overall, the prevalence of penile quadrivalent HPV vaccine (4vHPV)-type HPV was similar in vaccinated participants (12.1%) and participants with no or unknown vaccination (15.6%) (adjusted prevalence ratio, 0.69 [95% confidence interval, .47-1.01]). However, the prevalence was significantly lower in participants vaccinated at age ≤18 years than in those with no of unknown vaccination (0.15 [.04-.62]), corresponding to a vaccine effectiveness of 85% against 4vHPV-type HPV.Conclusions: Results suggest that HPV vaccination is effective in preventing penile HPV infections in young MSM when administered at age ≤18 years. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Sexual Positioning Practices and Anal Human Papillomavirus Infection Among Young Men Who Have Sex with Men and Transgender Women-Chicago, Illinois, 2016-2018.

Author

Morgan, Ethan, Meites, Elissa, Markowitz, Lauri E., Hall, Casey D. Xavier, Querec, Troy D., Unger, Elizabeth R., Crosby, Richard A., Newcomb, Michael E., Mustanski, Brian, and Xavier Hall, Casey D

Abstract

Background: Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States; men who have sex with men (MSM) have higher prevalence of infection and related disease compared with other men. We assessed whether differences in HPV acquisition exist among MSM according to their sexual positioning practices, as well as self-reported receipt of HPV vaccination.Methods: We enrolled young MSM and transgender women aged 18 to 26 years in Chicago, IL (N = 666). Participants self-reported their history of HPV vaccination and submitted self-collected anal swab specimens for type-specific HPV detection using an L1-consensus PCR assay. Multivariable logistic regression analyses were used to assess relationships between sexual positioning practices and detection of any HPV or quadrivalent HPV vaccine (4vHPV) types by vaccination status, defined as self-reported receipt of ≥1 HPV vaccine dose versus none.Results: Among 666 participants, 400 (60.1%) had any anal HPV, and 146 (21.9%) had a 4vHPV type. Among vaccinated participants, 18, 36, and 177 reported exclusively insertive, exclusively receptive, or both sexual positioning practices, respectively. Compared with participants reporting exclusively insertive anal sex, odds of any HPV were significantly higher among participants engaging exclusively in receptive anal sex (adjusted odds ratio [aOR], 5.90; 95% confidence interval [CI], 2.52-13.78), as well as those engaging in both (aOR, 3.32; 95% CI, 1.71-6.44). Vaccinated participants, compared with unvaccinated participants, had lower odds of 4vHPV-type HPV regardless of sexual positioning practices (aOR, 0.56; 95% CI, 0.34-0.92).Conclusions: Adult men and transgender women who practice anal receptive sex have high prevalence of infection with any HPV. Routine vaccination of all adolescents is expected to reduce HPV-related disease incidence among adult MSM and transgender women as vaccinated cohorts age. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results